updat model reflect management direct guidanc modestli q/
 impli lower estim
sequenti also given reaffirm guidanc despit beat
quarter increment posit outlook think potenti upsid
particularli
management note expect adj ep modestli
anticip sequenti declin attribut invest drive long-term
growth expect increas sg spend smaller scale contract renew
modestli lower volum due certain custom experienc financi distress
lower adj ep estim sequenti
despit beat primarili attribut oper
out-performance pharma medic segment guidanc remain
unchang lead us believ potenti upsid futur management
note elect rais guidanc given one quarter fiscal
year see number factor could impact financi perform subsequ
quarter includ medic devic tax tariff gener program brand inflat
could materi impact thing equal reaffirm
guidanc commentari expect modestli sequenti
suggest back-half assum consider amount conservat
rais adj ep estim
respect also rais price target base revis
dcf analysi impli share trade adj ep estim
pleas see page report import disclosur
would remain sidelin demonstr consist perform
medic segment plagu number issu howev
fundament pharma seem stabil improv management appear
execut stabil medic follow issu cordi medic solut addit
execut cost reduct streamlin initi increment posit
comment regard progress toward reach global opioid settlement suggest
overhang relat opioid litig eas may elimin event global
progress turnaround medic
updat management strateg initi
growth
gross margin almost
ebit margin
share repo
top-lin growth high-singl digit
due better expect growth
specialti medic
gross margin closer greater
expect benefit red oak
perform medic
sg come better oper
leverag cost reduct
share repo greater
top-lin growth low-singl
digit due weaker expect
gross margin due weaker
expect gener profit
 restructur cost weigh
share repo less
one three largest pharmaceut distribut compani
 oper billion pharmaceut market compani distribut
comprehens offer brand-nam gener pharmaceut over-the-count
healthcar product home healthcar suppli equip wide varieti
healthcar provid locat throughout includ acut care hospit health
system independ chain retail pharmaci mail-ord facil physician clinic
alternate-sit facil cardin oper today two report segment
pharmaceut medic cardin recent focus home health space
million except per-shar data
compani report cowen compani
changevariancetot good gross gross bp chang gener oper oper interest pre-tax pre-tax incom tax net incom continu net incom deal-rel discontinu operations- nm- non-recurring net incom weight averag continu ep deal-rel ep non-recurring ex-disc ep oper oper bp chang medic oper oper bp chang cowen
million except per-shar data
cowen compani
model assumptionstermin growth tax depreci chang work terminal- capit valuefre pv npv free npv futur excess valu total number valu per fiscal year end june cowen
million except per-shar data
compani report cowen compani
good gross gross chang sell gener oper interest pre-tax incom tax incom continu net incom deal-rel discontinu operations- non-recurring net incom dilut weight averag ep continu ep deal-rel ep non-recurring ex-disc ep chang year-over-year oper incom continu continu year end june cowen
million except per-shar data
compani report cowen compani
good gross gross chang sell gener oper interest pre-tax pre-tax incom tax net earn attribut non-controlling net incom continu net incom deal-rel discontinu operations- non-recurring net incom dilut weight averag adj chang year-over-year oper incom continu continu cowen
million
compani report cowen compani
asset trade receiv merchandis prepaid expens asset held sale discontinu ops- current pp goodwil total current liabil current portion long-term account accru liabil busi held sale disc ops- current long-term defer tax redeem non-controlling stockhold equiti common retain common share cumul foreign currenc non-controlling total stockhold total liabil stockhold short-term liquid ratio current sale day purchas account inventori ratio inventori capit structur long-term solvenc ratio total debt total interest ratio return invest capit averag total asset averag stockhold equiti year end june cowen
million
compani report cowen compani
income/ loss cumul effect chang accounting- earn /loss discontinu operations- earn cont op b/f effect chg flow oper activ depreci sale provis loss account charg reorg busi charges- sale invest businesses- employe stock defer incom invest impair chang oper asset liabil account merchandis prepaid expens assets- account oper net cash use /provid op activ disc ops- net cash oper acquisit properti acquisit issuanc common purchas treasuri dividend common proceeds/ purchas secur proceeds/ repay debt net increase/ decreas cash equival begin cash equival end cowen summari capit owner financ non-recur year end june cowen
million
compani report cowen compani
flow oper activitiesnet cumul effect chang accounting- earn /loss discontinu earn cont op cumul effect chang adjust reconcil net earn net cash depreci sale asset loss debt sale carefus common stock- purchas in-process d- equiti provis defer incom tax provis bad debt chang fair valu conting consider oblig chang oper asset liabil net increas trade receiv increas increas net invest sales-typ leases- increas account oper item net net cash use /provid oper activ discontinu ops- net cash provid oper flow invest activ acquisition/divestitur subsidiari net cash acquir proce sale properti equip addit properti equip sale/ purchas market secur avail sale proce matur available-for-sal proce divestitur dispos held sale proce sale carefus common stock- net cash use /provid invest activ discontinu ops- net cash use invest flow financ activ payment conting net chang commerci paper short-term debt reduct long-term oblig net purchas non-controlling interests- proce interest rate swap terminations- proce long-term oblig net issuanc cost proce securit borrow payment premium debt extinguishment- proce issuanc common share tax benefit exercis stock purchas treasuri share net cash use /provid financ activ discontinu ops- net cash provid by/ use financ effect exchang rate chang cash equivalents- reclassfii asset held sale- net increas decreas chang fiscal year equival begin equival end fiscal year end june cowen
use five-year discount cash flow analysi primari valuat method
deriv price target gener assum discount rate may appli
appropri adjust depend compani and/or industri specif factor also
assum termin growth rate depend long-term view specif
sub-industri coverag note discount rate assumpt could view
conserv rel actual weight averag cost capit view
assumpt reason long run lower discount rate assumpt
increas termin growth rate assumpt would lead higher estim valu
per share secondari measur look forward price-to-earnings multipl ev/sal ratio
impli dcf analysi compar histor averag
potenti risk associ drug distribut space industri
highli competit could pressur margin core drug distribut busi
current wave drug patent expir posit impact profit
deriv gener expect taper significantli next sever year
specialti provid signific tailwind industri concern
around sustain high growth biotech sector longer term
impact ppaca expect increas volum could subdu depend
implement execut
number company-specif risk associ pt includ
abil execut medic strategi cost reduct either wors better management
expect opioid litig expens greater expect manag abil
deploy capit effect
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock secur
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
